Evofem Biosciences Inc

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, June 1, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Saundra Pelletier, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows: Date:  Friday, June 4, 2021 Time:  10:30 a.m. ET (7:30 a.m.

Evofem Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

Iterum Therapeutics Plc

T2 Biosystems

With biotech penny stocks back in focus, which small-caps are you watching? The post Hot Biotech Penny Stocks To Buy?

Hot Biotech Penny Stocks To Buy? 3 to Watch Right Now

SAN DIEGO, May 25, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on Tuesday, June 8, 2021 at 1:00 p.m. ET (10:00 a.m.

Evofem Biosciences to Present at LD Micro Invitational XI on Tuesday, June 8, 2021

SAN DIEGO, May 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to purchase an aggregate of up to 50 million shares of common stock. In addition, Evofem granted the underwriter a 30-day option to purchase up to an additional 7.5 million shares of its common stock and/or accompanying warrants to purchase an aggregate of up to 7.5 million shares of its common stock, which the underwriter has partially exercised for warrants to purchase an aggregate of up to 7.5 million shares of common stock.

Evofem Biosciences Announces Closing of $50 Million Public Offering

EVFM stock is plunging after the women's health company announced and priced a stock and warrant offering. The post EVFM Stock: One Big Reason Why Evofem Biosciences Is Plunging Today appeared first on InvestorPlace.

EVFM Stock: One Big Reason Why Evofem Biosciences Is Plunging Today

Evofem Biosciences Inc (NASDAQ: EVFM) has priced its previously announced underwritten public offering of 50 million shares and accompanying short-term warrants to purchase up to an aggregate of 50 million shares. The offer price of $1.00 per share represents a discount of 22% from the last close price of $1.28 on Monday.

Evofem Biosciences Stock Plunges On Raising $50M Via Equity At 22% Discount

The stock price of Evofem Biosciences Inc (NASDAQ: EVFM) decreased by over 35% pre-market. This is why it happened.

Evofem Biosciences (EVFM): Over 35% Decrease Pre-Market Explanation

SAN DIEGO, May 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the pricing of its previously announced underwritten public offering of 50,000,000 shares of its common stock and accompanying short-term warrants to purchase up to an aggregate of 50,000,000 shares of common stock. Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock at a combined public offering price of $1.00 per share of common stock and accompanying common warrant, less underwriting discounts and commissions.

Evofem Biosciences Announces Pricing of $50 Million Public Offering

SAN DIEGO, May 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that new research on its investigational drug EVO100 for the prevention of chlamydia and gonorrhea in women will be highlighted in a poster presentation at the annual meeting of the Professional Society for Health Economics and Outcomes Research, Virtual ISPOR 2021, which will be held May 17 to 20, 2021.  Abstract: 108785 Title:      Assessing the Understandability and Importance of Patient Reported Outcomes Impacting Adherence and Outcomes of a Non-Hormonal Vaginal Microbicide to Protect Against Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (GC) Authors: Robert Morlock, PhD; Lalitha Aiyer, MD, MS, MBA, FAIHM; Kelly Culwell, MD, MPH, FACOG; Brandon Howard, PhD Date:  Tuesday, May 18, 2021 Qualitative research was conducted among 21 women with previous experience with EVO100.

New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021

Fulcrum Therapeutics Inc

The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is on track to report full data from the ReDUX4 Phase 2b trial at the virtual FSHD International Research Congress to be held next month.

Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation

Minerva Neurosciences

Novan

Obalon Therapeutics

Biotech penny stocks are heating up right now; here's 4 to watch The post Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May

SAN DIEGO, May 12, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women. Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs.

Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women

Cellect Biotechnology Ltd

Atossa Genetics

22nd Century Group

Looking for the best penny stocks in May 2021? Check these 5 out The post 5 Hot Penny Stocks To Buy?

5 Hot Penny Stocks To Buy? Check These Out For May 2021

Phexxi new prescriptions are being generated at a higher rate than I modeled in my valuation estimates.

Evofem: Phexxi Scripts Tracking Ahead Of Model, But Market Is Unimpressed

The stock price of Evofem Biosciences Inc (NASDAQ: EVFM) increased by over 5% pre-market. This is why it happened.

EVFM Stock: Over 5% Increase Pre-Market Explanation

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q1 2021 Results - Earnings Call Transcript

SAN DIEGO, May 6, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three-month period ended March 31, 2021. First quarter and recent highlights include: Direct-to-consumer (DTC) marketing campaign launched on February 14, 2021 resulting in: 83% total prescription growth for Phexxi® (lactic acid, citric acid and potassium bitartrate) in March vs.

Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, April 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two new data sets from its Phase 3 AMPOWER trial evaluating Phexxi® (lactic acid, citric acid, potassium bitartrate) will be presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM). The meeting will be conducted virtually from April 30 - May 2, 2021.

Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting

SAN DIEGO, April 22, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the first quarter ended March 31, 2021 as follows:   Date Thursday, May 6, 2021 Time 4:30 p.m. ET (1:30 p.m.

Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021

SAN DIEGO, April 21, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced the company will deliver the keynote address and present two poster presentations on Phexxi® (lactic acid, citric acid, potassium bitartrate) at the upcoming NCODA 2021 National Spring Forum, which will be held April 28 to 30 as a virtual E-Meeting. CEO Saundra Pelletier will deliver a keynote address entitled Evofem Biosciences and NCODA Partnering to Raise Awareness About Phexxi: Supporting the Reproductive and Sexual Health of Women with Cancer on Wednesday, April 28 at 12:05pm PT.

Evofem Biosciences to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring Forum

SAN DIEGO, March 29, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 17,142,857 shares of its common stock at $1.75 per share.  Evofem's aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $30.0 million.

Evofem Biosciences Announces Closing of Public Offering of Common Stock

F-Star Therapeutics Inc

Immutep Ltd

ProQR Therapeutics

Cellect Biotechnology Ltd. (NASDAQ: APOP), Immutep Limited (NASDAQ: IMMP), F-star Therapeutics, Inc. (NASDAQ: FSTX), ProQR Therapeutics N.V.

Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday

Shares of Evofem Biosciences Inc. tumbled 24.9% toward a record low in premarket trading Thursday, after the biopharmaceutical company focused on women's sexual and reproductive health announced the pricing of a relatively large public stock offering at a deep discount. The company said its pricing of 17.14 million shares, representing about 20.6% of the shares outstanding as of Feb. 28, priced at $1.75 to raise $30 million.

Evofem Biosciences stock tumbles toward a record low, after public stock offering prices at 25% discount

SAN DIEGO, March 24, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a price to the public of $1.75 per share. The gross proceeds from the offering to Evofem, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $30.0 million.

Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common Stock

SAN DIEGO, March 24, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to offer and sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional $4.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions.

News for Evofem Biosciences Inc Stock (EVFM)